Compare Novavax Inc (NVAX) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs J M Smucker Co — how do they compare? Novavax Inc trades at $12.54 (market cap $1.82B), while J M Smucker Co trades at $118.62 (market cap $12.76B). The key difference: J M Smucker Co is far larger — about 7× Novavax Inc's market cap, and J M Smucker Co pays a 3.75% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and J M Smucker Co for 74 Days on average.
| NVAX | SJM | |
|---|---|---|
Market Cap | $1.82B | $12.76B |
Volume | 6,198,505 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $12.56 | $132.34 |
52-Week Low | $6.22 | $89.53 |
Typical Hold Time | 59 Days | 74 Days |
Enterprise Value | $1.39B | $19.61B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
SJM trades at $115.93, down 0.74% on the day, with a bearish technical signal and recent earnings beats. The company reported a net loss of $1.23 billion in 2025 despite revenue growth to $8.73 billion, though 2026 forecasts show a return to profitability. Analyst consensus is bullish with a $138.23 price target, and a $1.12 dividend is scheduled for September 2026.
The stock presents a mixed outlook: strong analyst support and dividend yield offer upside, but high P/E of 55.8 and recent net losses pose valuation and execution risks. Key catalysts include sustained earnings growth and margin improvement, while competitive pressures and debt levels remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
